2Colevas AD,Setser A,CTEP/NCI,et al.The NCI common Terminology Criteria for Adverse Events (CTCAE) v3.0 is the new standard for oncology clinical trials[J].Clin Oncol,2008,22(14S):176-181.
3Glinelius B,Ekstrom K,Hoffman K,et al.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer[J].Ann Oncol,2010,8:163-168.
4Giuliani F,Gebbia V,De Vita F,et al.Docetaxel as salvage therapy in advanced gastric cancer:a phase Ⅱ study of the Gruppo Oncologico Italia Meridionale (G.O.I.M)[J].Anticancer Res,2003,23(5b):65-67.
5Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors [J]. Cancer, 1996, 77(2):362-372.
6Huang AP, Tsai JC, Kuo LT, et al. Clinical application of perfusion computed tomography in neurosurgery [ J ]. J Neu- rosurg, 2014,120(2) :473-488.
7Matsumura T, Hayakawa M, Shimada F, et al. Safety of ga- dopentetate dimeglumine after 120 million administrations over 25 years of clinical use [ J ]. Magn Reson Med Sci, 2013,12(4) :297-304.
8Yang L, Krefting I, Gorovets A, et al.Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration [ J ]. Radiology, 2012,265( 1 ) :248-253.
9Tan H, Chen L, Guan Y, et al. Comparison of MRI, F-18 FDG, and 11 C-choline PET/CT for their potentials in differ- entiating brain tumor recurrence from brain tumor necrosis following radiotherapy[J]. Clin Nucl Med, 2011,36( 11 ) : 978-981.
10Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive con- trast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastie contrast-enhancing tissue [ J ]. Am J Neuroradiol,2000,21 (5) :901-909.
